BioRestorative Therapies Inc (BRTX) Noticias

lets hope so the past years are depressing

NEWS...get it before it's gone...

BioRestorative to Provide a Positive FDA Update on Clinical Pipeline

https://www.globenewswire.com/news-release/2025/02/25/3031975/0/en/BioRestorative-to-Provide-a-Positive-FDA-Update-on-Clinical-Pipeline.html

Interesting news out today as well as the breakout support.
Looks like this one is ready to leave the station.

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program
February 20, 2025 08:30
https://www.globenewswire.com/news-release/2025/02/20/3029644/0/en/BioRestorative-Receives-FDA-Fast-Track-Designation-for-BRTX-100-Chronic-Lumbar-Disc-Disease-Program.html

Going $2.90s + 40%!careful known to dump quickly 5m floater 

After all these years, it's nice to see the test results.

Hey Monk do you ever have a dream where this gets back above $2? Hoping so.

BRTX under $2

BRTX under $2

BRTX under $2

BRTX.........................................https://stockcharts.com/h-sc/ui?s=BRTX&p=W&b=5&g=0&id=p86431144783

$15.00 ... lets hope so someday - Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: $BRTX), Says “Low Valuation Undeserved” https://finance.yahoo.com/news/roth-mkm-analyst-projects-impressive-130000497.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

As of June 10, 2024 there were 6,769,919 shares of the registrant’s Common Stock outstanding. $BRTX

Aren’t they all unless a big cap stock

Pump and dump.

BRTX...................................................https://stockcharts.com/h-sc/ui?s=BRTX&p=W&b=5&g=0&id=p86431144783

BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program

BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

BRTX under $2

I’m very happy to see Auct-ass going down.

BRTX under $2

$BRTX. so sad
BIORESTORATIVE THERAPIES INC
$1.57-1.88 (-54.49%)

BRTX new 52 week low

That didn’t age well. Just got dumped on with new warrants and more dilution!! It’s a scam like the others u mentioned.

Aaaaand down she goes. Lance is scum of the earth and this is a scam.

Back down again

sure has - $BRTX

It's been a long time coming.

Nice to see the team pulling this out of the fire.

spike to 4.50,she can really fly, "FLY MY PRETTY!!" 60% move from close is beautiful

Out at 4.34

$BRTX BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc. (“BioRestorative”, “$BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced the public availability of a poster, presented yesterday at the Orthopaedic Research Society (ORS) 2024 Annual Meeting, which describes preliminary 26 and 52 week blinded data from the ongoing Phase 2 clinical trial of the Company’s lead clinical candidate, BRTX-100, in subjects with chronic lumbar disc disease (“cLDD”).
The presented poster, titled “Autologous Stem Cell Therapy for Chronic Lumbar Disc Disease; Initial Phase 2 Clinical Safety and Feasibility Data of Intradiscal Injections of Hypoxic Cultured Mesenchymal Stem Cells” can be accessed on the Company’s website at www.biorestorative.com under “Scientific Publications” in the Product Candidate section. During a webcasted conference call scheduled for 8:30am EST today, BioRestorative management will be available to discuss data from the presentation as well as provide a clinical update.

Previous clinical studies have demonstrated that the harsh microenvironment of the disc could impact cell dose viability and result in a non-efficacious or the worsening of clinical outcomes. Although this is blinded and early clinical data, it is important to note that the Visual Analog Scale, Oswestry Disability Index, Roland Morris Disability Questionnaire, and Functional Rating Index collected at weeks 26 and 52 post-injection demonstrated a positive trend compared to baseline. In addition to safety outcomes, changes to these pain and function scales compared to baseline are used by the U.S. Food and Drug Administration (FDA) to determine whether the trial will be allowed to proceed and ultimately gain Biologics License Application (BLA) approval.

“We are thrilled with the progress of our ongoing clinical development programs. With regard to the Phase 2 study investigating the use of BRTX-100 in the treatment of cLDD, we are strongly encouraged by the preliminary data presented at ORS 2024. The preliminary clinical data shows meaningful signals in patients enrolled in the study and, importantly, no notable safety signals,” said Lance Alstodt, Chief Executive Officer of BioRestorative.

Liking PM.

6month high Fri.,and look at the green on the candles on here,tremendous buying going on.

New 2 day high,vol increase,I am excited

They seem excited;)
https://www.biorestorative.com/press-releases/

Conference call/presentation on Mon at 8:30am est,last time stock was halted until presentation was over.

Looking good for Monday

debt only 198K (yahoo finance info)

12M cash,,no offerings/no warrents endlessly dumping like most other tickers that trade 10m-30m shares and never move up,BRTX went up 25% on 500k

Roth mkm analyst's target $15.00

demand building,40K@ 2.60(the moving ave support)

10Xs ave vol,165Xs relative buying vol!!!!,exceeded yesterdays total vol already today

watch for bounce off ma's @ 2.60

conf. call monday,prelimb data/current plans,patent approval was dec.12th,poked thru the sma200 today @2.88(blue sky ma resistance above that,last time it poked thru it ran up 100%)

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® program. The notice of allowance was issued on October 26, 2023. The application is scheduled to issue as U.S. Patent No. 11,851,682 on December 26, 2023.
This will be the fourth U.S. patent granted under this particular patent family. Claims granted under the new patent cover methods of using differentiated human brown fat adipocytes as a platform to screen and identify compounds that can activate and regulate metabolic activity. These compounds, if discovered to provide metabolic benefits, can then be further developed into drugs targeting weight loss. Therapeutic benefits of using activated brown adipose have been demonstrated in various models and may provide a valuable therapeutic tool for treating a range of metabolic disorders. For example, studies have shown that GLP-based therapeutics interact with brown adipose tissue.

“This notice of allowance is an important milestone as it provides us with tools that can be used as a platform to screen large libraries of compounds targeting metabolic disorders such as obesity,” said Lance Alstodt, the Company’s CEO. “The prevalence of developmental pipelines targeting obesity has increased substantially over the past year. As a result there is a need for more advanced targeted and precise tools and methods for identifying such compounds. This notice of allowance will afford us the protections necessary to allocate resources to develop these extremely valuable tools.”

I have way too much money in this stock. Maybe I will see profits in a year or two. Sheesh!!!!

Everything is going great at the company level.... why isn't the stock appreciating?

Very disappointing performance

BRTX under $2